Prof. Dr. SAADETTİN KILIÇKAP

Yayın Ağı

Makaleler 162

1. **Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial**

Peters S., Gadgeel S. M., Mok T., Nadal E., KILIÇKAP S., Swalduz A., et al.

NATURE MEDICINE , cilt.30, ss.1923-1932, 2024 (SCI-Expanded, Scopus)

2. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.

Clinical Genitourinary Cancer , cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)

3. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

KILIÇKAP S., Ozturk A., Karadurmus N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al.

MEDICINE , cilt.103, sa.21, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.

International Journal of Clinical Oncology , cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)

5. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Zhou C., Hu Y., Arkania E., Kilickap S., Ying K., Xu F., et al.

Cancer cell , cilt.42, sa.2, ss.198-208, 2024 (SCI-Expanded, Scopus)

6. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.

Cancer Medicine , cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)

7. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.

Journal of Chemotherapy , 2024 (SCI-Expanded, Scopus)

8. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

Cicin I., Karadurmus N., BİLİCİ A., Bahsi T., ŞENDUR M. A. N., Demirci U., et al.

FUTURE ONCOLOGY , cilt.20, sa.15, ss.1031-1045, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.

Journal of Immunotherapy and Precision Oncology , cilt.6, sa.4, ss.170-176, 2023 (Scopus)

10. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)

11. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)

12. Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study

ÖZDEMİR N., AKTAŞ B. E., Gulmez A., İNKAYA A. Ç., Bayraktar-Ekincioglu A., Kilickap S., et al.

Supportive Care in Cancer , cilt.31, sa.3, 2023 (SCI-Expanded, Scopus)

13. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)

14. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., et al.

Clinical Genitourinary Cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

15. Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab

Elmali A., GÖÇMEN R., KILIÇKAP S., YAZICI G.

Journal of Oncology Pharmacy Practice , 2023 (SCI-Expanded, Scopus)

16. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.

BREAST , cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)

17. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Yekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded, Scopus)

18. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Yucel K. B., Yekeduz E., Karakaya S., Tural D., Erturk I., EROL C., et al.

SCIENTIFIC REPORTS , cilt.12, sa.1, 2022 (SCI-Expanded, Scopus)

19. Oncologists' attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study

Kandemir E. A., EKİNCİOĞLU A., KILIÇKAP S.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.7, ss.1560-1567, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)

21. Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab

MENTEŞOĞLU D., DOĞAN GÜNAYDIN S., ERSOY EVANS S., Atakan N., GÖKÖZ Ö., KARADAĞ Ö., et al.

INDIAN JOURNAL OF PHARMACOLOGY , cilt.54, sa.4, ss.295-296, 2022 (SCI-Expanded, Scopus)

22. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., et al.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.53, sa.2, ss.282-288, 2022 (ESCI, Scopus) Sürdürülebilir Kalkınma

23. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.

CANCERS , cilt.14, sa.11, 2022 (SCI-Expanded, Scopus)

24. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

25. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study

Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.4, 2022 (SCI-Expanded, Scopus)

26. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.

Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.6, 2022 (SCI-Expanded, Scopus)

27. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.

Bosnian Journal of Basic Medical Sciences , cilt.22, sa.5, ss.818-825, 2022 (SCI-Expanded, Scopus)

28. Pazopanib-induced chylothorax in a patient with renal cell carcinoma

KÖYLÜ B., TEKİN F., AKTAŞ B. Y., KILIÇKAP S., KÖKSAL D.

ANTI-CANCER DRUGS , cilt.33, sa.1, 2022 (SCI-Expanded, Scopus)

29. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.

FUTURE ONCOLOGY , cilt.17, ss.4861-4869, 2021 (SCI-Expanded, Scopus)

30. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.

CURRENT PROBLEMS IN CANCER , cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)

31. Thirty-day mortality rates after immunotherapy initiation

SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., et al.

IMMUNOTHERAPY , cilt.13, ss.1419-1426, 2021 (SCI-Expanded, Scopus)

32. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.

FUTURE ONCOLOGY , cilt.17, ss.4405-4413, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

33. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.

FRONTIERS IN ONCOLOGY , cilt.11, 2021 (SCI-Expanded, Scopus)

34. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

35. Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department

ÖCAL O., Eldem G., KARAGÖZ A. H., KILIÇKAP S., YALÇIN Ş., BALKANCI F., et al.

CUREUS , cilt.13, sa.9, 2021 (ESCI)

36. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al.

CANCER INVESTIGATION , cilt.39, sa.6-7, ss.473-481, 2021 (SCI-Expanded, Scopus)

39. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.26, ss.1506-1513, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

40. Comparison of respiratory muscle strength and endurance, maximal oxygen consumption, and fatigue in colorectal cancer survivors with healthy adults

Sanver M. F., VARDAR YAĞLI N., SAĞLAM M., TEKERLEK H., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.7, ss.3903-3909, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded, Scopus)

42. The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients

ÖZDEMİR N., Bayraktar-Ekincioglu A., KILIÇKAP S.

MEDICAL ONCOLOGY , cilt.38, sa.6, 2021 (SCI-Expanded, Scopus)

43. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.

Ozguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

44. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

45. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.36, 2021 (SCI-Expanded, Scopus)

46. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

47. Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy

Kandemir E. A., EKİNCİOĞLU A., KILIÇKAP S.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.3, ss.1699-1709, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

48. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Sezer A., KILIÇKAP S., GÜMÜŞ M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., et al.

LANCET , cilt.397, sa.10274, ss.592-604, 2021 (SCI-Expanded, Scopus)

49. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

50. Factors affecting the response to Y-90 microsphere therapy in the cholangiocarcinoma patients

Bozkurt M., Eldem G., Bozbulut U. B., BOZKURT M. F., KILIÇKAP S., PEYNİRCİOĞLU B., et al.

RADIOLOGIA MEDICA , cilt.126, sa.2, ss.323-333, 2021 (SCI-Expanded, Scopus)

51. Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group

Akagunduz B., AKIN TELLİ T., YILDIRIM H. Ç., SEZGİN GÖKSU S., DEMİR N., Hafizoglu E., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.31, sa.2, ss.92-98, 2021 (SCI-Expanded, Scopus, TRDizin)

52. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus)

53. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives

C Guven D., ŞAHİN T. K., DİZDAR Ö., KILIÇKAP S.

BIOMARKERS IN MEDICINE , cilt.14, ss.1383-1392, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

54. Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

HIZAL M., ŞENDUR M. A. N., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus)

55. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer

Uruen Y., Hussain S. A., Bakouny Z., Castellano D., KILIÇKAP S., Morgan G., et al.

JCO GLOBAL ONCOLOGY , cilt.6, ss.1248-1257, 2020 (ESCI, Scopus)

56. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19

GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.

FRONTIERS IN ONCOLOGY , cilt.10, 2020 (SCI-Expanded, Scopus)

57. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., et al.

JOURNAL OF BUON , cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded, Scopus)

58. The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis

Eren M. F., Eren A. A., Sayan M., YÜCEL B., Elagoz S., Ozguven Y., et al.

MEDICINA-LITHUANIA , cilt.56, sa.7, 2020 (SCI-Expanded, Scopus)

59. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

YAŞAR H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

60. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic

Kucuk E., EKİNCİOĞLU A., ERMAN M., KILIÇKAP S.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.3, ss.595-602, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

61. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.2, ss.496-499, 2020 (SCI-Expanded, Scopus)

62. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study

Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.2, ss.267-272, 2020 (SCI-Expanded, Scopus)

63. Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience

Karakas Y., Lacin S., KURTULAN O., Esin E., Sunar V., SÖKMENSÜER C., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.2, ss.91-98, 2020 (SCI-Expanded, Scopus, TRDizin)

64. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.1, ss.256-258, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

65. The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer

Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M., Xiao L., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.30, sa.2, ss.94-102, 2020 (SCI-Expanded, Scopus, TRDizin)

66. Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?

ÜRÜN Y., Yasar H. A., TURNA Z. H., KILIÇKAP S., Sezer A., Oksuzoglu B., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.25, sa.8, ss.2062-2063, 2019 (SCI-Expanded, Scopus)

67. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study

ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.25, sa.7, ss.1658-1664, 2019 (SCI-Expanded, Scopus)

68. Adaptation of Error Adjusted Bagging Method for Prediction

Isikhan S., KARABULUT E., Samadi A., KILIÇKAP S.

INTERNATIONAL JOURNAL OF DATA WAREHOUSING AND MINING , cilt.15, sa.3, ss.28-45, 2019 (SCI-Expanded, Scopus)

69. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience

TÜRK G., Eldem G., KILIÇKAP S., Bozkurt F. M., VOLKAN SALANCI B., ÇİL B. E., et al.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.50, sa.2, ss.236-243, 2019 (ESCI, Scopus) Sürdürülebilir Kalkınma

70. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients

Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

BIOMARKERS IN MEDICINE , cilt.13, sa.9, ss.725-735, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

71. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability

KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.83, sa.6, ss.1195-1196, 2019 (SCI-Expanded, Scopus)

72. Reproductive cancer risk factors among relatives of cancer patients in a tertiary oncology center

Atta N., KILIÇKAP S., YÜCE D., Hayran M.

BMC CANCER , cilt.19, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

73. Critical Role of Ga-68 DOTATATE PET-CT in a Patient with Neuroendocrine Tumor and Second Primary Cancer

TELLİ T., TUNCEL M., KILIÇKAP S.

TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM , cilt.23, sa.1, ss.58-63, 2019 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

74. Sicca/Sjogren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)

Ramos-Casals M., Maria A., Suarez-Almazor M. E., Lambotte O., Fisher B. A., Hernandez-Molina G., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.37, sa.3, 2019 (SCI-Expanded, Scopus)

75. EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER

KILIÇKAP S.

NOBEL MEDICUS , cilt.14, sa.3, ss.5-8, 2018 (ESCI, Scopus) Sürdürülebilir Kalkınma

76. Factors associated with quitting action following smoking cessation counseling.

Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYIN B.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

77. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results

ARMAĞAN B., SARI A., ERDEN A., KILIÇ L., ERDAT E. C., KILIÇKAP S., et al.

MEDICINE , cilt.97, sa.13, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Changes in lifestyle upon diagnosis of cancer or other chronic illnesses: A Turkish Oncology Group study

Turhal N. S., Akinci F., Haciabdullahoglu Y., Dolmaci M., Sari A., GÜRHAN N., et al.

JOURNAL OF HEALTH PSYCHOLOGY , cilt.23, sa.4, ss.561-566, 2018 (SSCI, Scopus) Sürdürülebilir Kalkınma

79. Evaluation of G-CSF (granulocyte colony stimulating factor) use in oncology outpatient clinic by the PRS (patient risk score) assessment

ARAS E., Tecen K., Bayraktar-Ekincioglu A., Demirkan K., KILIÇKAP S.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , cilt.40, sa.1, ss.247, 2018 (SCI-Expanded, Scopus)

80. Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors

Tecen-Yucel K., Bayraktar-Ekincioglu A., KILIÇKAP S., ERMAN M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.28, sa.1, ss.53-60, 2018 (SCI-Expanded, Scopus, TRDizin)

81. Epidemiyoloji ve Etiyoloji

YÜCE D., KILIÇKAP S.

Türkiye Klinikleri Tip Bilimleri Dergisi , 2018 (Scopus, TRDizin)

82. Endpoints in oncology clinical trials

KILIÇKAP S., Demirci U., Karadurmus N., Dogan M., Akinci B., ŞENDUR M. A. N.

JOURNAL OF BUON , cilt.23, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

83. BİR SİGARA BIRAKMA POLİKLİNİĞİNDE UYGULANAN PSİKOEĞİTİMSEL SİGARA BIRAKMA POROGRAMININ ETKİNLİĞİ

KAMIŞLI S., YÜCE D., küçükçoban ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.

Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi , cilt.20, sa.4, ss.234-242, 2017 (TRDizin)

84. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient

Karakas Y., YÜCE D., KILIÇKAP S.

ONCOLOGY RESEARCH AND TREATMENT , cilt.40, sa.10, ss.621-622, 2017 (SCI-Expanded, Scopus)

85. Reinforcement of mental health in an interaction group of cancer patients

HAYRAN K. M., Kamisli S., Kucukcoban S., ÇELİK İ., KILIÇKAP S., YÜCE D.

PSYCHO-ONCOLOGY , cilt.26, ss.161, 2017 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

86. Cancer patients and oncology nursing from the perspectives of oncology nurses in Turkey

Kamisli S., YÜCE D., Karakilic B., KILIÇKAP S., HAYRAN K. M.

PSYCHO-ONCOLOGY , cilt.26, ss.145, 2017 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

87. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?

Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., KILIÇKAP S., et al.

SAUDI JOURNAL OF GASTROENTEROLOGY , cilt.23, sa.3, ss.183-189, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

88. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database

DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.

JOURNAL OF BUON , cilt.22, sa.2, ss.530-534, 2017 (SCI-Expanded, Scopus)

89. Retention Rate of Etanercept in Patients with Rheumatoid Arthritis Is Better Than That of Monoclonal Antibody

ERDEN A., KILIÇ L., KARADAĞ Ö., KİRAZ S., KILIÇKAP S., AKDOĞAN A., et al.

Acta Medica , cilt.48, sa.3, ss.11-17, 2017 (TRDizin)

90. A giant polypoid mass leading to obstruction in the colon

KÖKLÜ H., ÖZTÜRK Ö., Koklu S., Saglam A., KARÇAALTINCABA M., KILIÇKAP S.

ACTA GASTRO-ENTEROLOGICA BELGICA , cilt.80, sa.1, ss.93-94, 2017 (SCI-Expanded, Scopus)

91. Attitudes of cancer patients after diagnosis: How cancer affects social life? A Turkish Oncology Group study

Nayir E., Koyuncu M. B., Esin E., Turker I., TANRIVERDİ Ö., UYSAL M., et al.

JOURNAL OF BUON , cilt.22, sa.1, ss.208-213, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

92. A critical analysis of publication rates of national oncology meeting abstracts in Turkey

KILIÇKAP S., Hüseyin B., Esin E., YÜCE D., HAYRAN K. M.

Journal of Oncological Sciences , ss.1-5, 2017 (TRDizin)

93. Evaluation of risk factors for the recurrence of colorectal polyps and colorectal cancer

ATEŞ Ö., SİVRİ B., KILIÇKAP S.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.47, sa.5, ss.1370-1376, 2017 (SCI-Expanded, Scopus, TRDizin)

94. Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer?

KILIÇKAP S., Tural D.

JOURNAL OF CLINICAL ONCOLOGY , cilt.34, sa.17, ss.2069-2070, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

95. Tendency of cancer patients and their relatives to use Internet for health-related searches: Turkish Oncology Group (TOG) Study

Nayir E., TANRIVERDİ Ö., Karakas Y., KILIÇKAP S., Turhal N. S., Avci N., et al.

JOURNAL OF BUON , cilt.21, sa.3, ss.714-719, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

96. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.

JOURNAL OF BUON , cilt.21, sa.2, ss.375-381, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

97. Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75

Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.2, ss.89-95, 2016 (SCI-Expanded, Scopus, TRDizin)

98. The prognostic value of UHRF-1 and p53 in gastric cancer

AKGÜL BABACAN N., EĞİLMEZ H. R., YÜCEL B., Parlak I., ŞEKER M. M., KAÇAN T., et al.

SAUDI JOURNAL OF GASTROENTEROLOGY , cilt.22, sa.1, ss.25-29, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

99. The Relationship of Agmatine Deficiency with the Lung Cancer

KAPANCIK S., ÇELİK V. K., KILIÇKAP S., Kacan T., Kapancik S.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.2, ss.103-109, 2016 (SCI-Expanded, Scopus, TRDizin)

100. Akciğer Kanserinde Erken Tanı ve Tarama Programlarındaki Gelişmeler

YÜCE D., KILIÇKAP S.

Turkiye Klinikleri Journal of Medical Oncology Special Topics , cilt.9, sa.4, ss.1-5, 2016 (TRDizin) Sürdürülebilir Kalkınma

101. The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism

Kacan T., YÜCEL B., BAHAR S., Celasun G., Seker M. M., Babacan N., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.3, ss.136-144, 2016 (SCI-Expanded, Scopus, TRDizin)

102. Effect of Zoledronic Acid on Rats' Tissue SDF-1 Expression

Arik Z., KILIÇKAP S., AKPULAT U., Nahit Sendur M. A., KOCAEFE Y. Ç., ERMAN M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.4, ss.215-219, 2016 (SCI-Expanded, Scopus, TRDizin)

103. Significant Association Between Polymorphisms of Wnt Antagonist Genes and Lung Cancer

YILMAZ M., DÖNMEZ G., KAÇAN T., SARI İ., Babacan N. A., SARİ M., et al.

JOURNAL OF INVESTIGATIVE MEDICINE , cilt.63, sa.8, ss.935-941, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

104. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study

Abali H., ÇELİK İ., Karaca B., TURNA Z. H., Saglam E. K., Akman T., et al.

JOURNAL OF BUON , cilt.20, sa.4, ss.1137-1141, 2015 (SCI-Expanded, Scopus)

105. QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION

HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.

VALUE IN HEALTH , cilt.18, sa.3, 2015 (SCI-Expanded, SSCI, Scopus)

106. Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter

Zoto T., KILIÇKAP S., YAŞAR Ü., ÇELİK İ., BOZKURT A., BABAOĞLU M. Ö.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , cilt.116, sa.4, ss.354-360, 2015 (SCI-Expanded, Scopus)

107. A Case of Multifocal Skin Metastases from Lung Cancer Presenting with Vasculitic-type Cutaneous Nodule

AKGÜL BABACAN N., KILIÇKAP S., Sene S., KAÇAN T., YÜCEL B., EREN M. F., et al.

INDIAN JOURNAL OF DERMATOLOGY , cilt.60, sa.2, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

108. Mortality in Colorectal Cancer and Use of Statins

Tural D., KILIÇKAP S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.33, sa.7, ss.810, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

109. First-Line Crizotinib in ALK-Positive Lung Cancer

Tural D., KILIÇKAP S.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.372, sa.8, ss.781, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

110. Nationwide Smoking Cessation Treatment Support Program - Turkey project

ÇELİK İ., YÜCE D., Hayran M., ERMAN M., KILIÇKAP S., BUZĞAN T., et al.

HEALTH POLICY , cilt.119, sa.1, ss.50-56, 2015 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

111. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML

Malkan U. Y., AKSU S., Aktimur S. H., Atay H., Bektas O., BÜYÜKAŞIK Y., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.25, sa.4, ss.215-221, 2015 (SCI-Expanded, Scopus, TRDizin)

112. HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS: EVALUATION WITH A SELF-ADMINISTERED IPAD APPLICATION

YÜCE D., HAYRAN K. M., KILIÇKAP S., ERMAN M., ÇELİK İ.

VALUE IN HEALTH , cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)

113. ASSOCIATION OF HEALTH CARE COST WITH QUALITY OF LIFE FOR VARIOUS TYPES OF CANCERS

HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.

VALUE IN HEALTH , cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)

114. Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival

Turkoz F. P., Solak M., KILIÇKAP S., Ulas A., Esbah O., Oksuzoglu B., et al.

JOURNAL OF GASTRIC CANCER , cilt.14, sa.3, ss.164-172, 2014 (ESCI, Scopus)

115. Study of interaction with a group of cancer patients: guiding cancer patients through psychoeducational interventions

Kamisli S., HAYRAN K. M., Kucukcoban S., KILIÇKAP S., YÜCE D., ÇELİK İ.

EUROPEAN JOURNAL OF ONCOLOGY NURSING , cilt.18, 2014 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

116. P95 HER2 fragments and breast cancer outcome

Tural D., Akar E., Mutlu H., KILIÇKAP S.

EXPERT REVIEW OF ANTICANCER THERAPY , cilt.14, sa.9, ss.1089-1096, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

117. Mortality in Prostate Cancer and Use of Statins

Tural D., YÜCE D., KILIÇKAP S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.32, sa.21, ss.2274, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

118. End-of-study results of Turkish gastric cancer patients from the global REGATE study

YALÇIN Ş., Gumus M., KILIÇKAP S., Alkis N., Ilhan M., Oksuzoglu B., et al.

JOURNAL OF BUON , cilt.19, sa.2, ss.377-387, 2014 (SCI-Expanded, Scopus)

119. Lung Cancer in Women: A Single Institution Experience with 50 Patients

AKGÜL BABACAN N., YÜCEL B., KILIÇKAP S., ŞEKER M. M., KAÇAN T., KOÇ OLÇAŞ İ., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.1, ss.151-154, 2014 (SCI-Expanded, Scopus)

120. Lack of Association between the MTHFR C677T Polymorphism and Lung Cancer in a Turkish Population

YILMAZ M., KAÇAN T., SARI İ., KILIÇKAP S.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.15, ss.6333-6337, 2014 (SCI-Expanded, Scopus)

121. Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer

KILIÇKAP S., KAYA Y., YÜCEL B., TUNCER E., AKGÜL BABACAN N., Elagoz S.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.3, ss.1381-1385, 2014 (SCI-Expanded, Scopus)

122. Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients

KESİKLİ S. A., KILIÇKAP S.

PROTEIN AND PEPTIDE LETTERS , cilt.20, sa.12, ss.1345-1359, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

123. Dose-dense effect: other contributors

KESİKLİ S. A., YÜCE D., KILIÇKAP S.

LANCET ONCOLOGY , cilt.14, sa.12, 2013 (SCI-Expanded, Scopus)

124. Aromatase Inhibitors and Safety: Clinical or Statistical Significance?

Esin E., YÜCE D., KILIÇKAP S., ERMAN M.

JOURNAL OF CLINICAL ONCOLOGY , cilt.31, sa.27, ss.3439, 2013 (SCI-Expanded, Scopus)

125. Evaluation of Quality of Life in Turkish Patients with Head and Neck Cancer

Akkas E. A., YÜCEL B., KILIÇKAP S., ALTUNTAŞ E. E.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.8, ss.4805-4809, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

126. Lack of Relationships between FGF19 Staining Pattern, Lymph Node Metastasis and Locally Invasive Characteristics of the Tumor in Colorectal Cancers

UNAL H. U., Demiralay E., Tepeoglu M., Fidan C., KILIÇKAP S.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.5, ss.3151-3154, 2013 (SCI-Expanded, Scopus)

127. Long-term complications in Hodgkin's lymphoma survivors

KILIÇKAP S., BARIŞTA İ., Ulger S., ÇELİK İ., SELEK U., Gullu I., et al.

TUMORI , cilt.98, sa.5, ss.601-606, 2012 (SCI-Expanded, Scopus)

128. Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature

ARSLAN Ç., KILIÇKAP S., YALÇIN Ş.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.22, sa.1, ss.73-76, 2011 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

129. Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature

Kurt M., KILIÇKAP S., AKSOY S., ERMAN M., Gedikoglu G., Turker A.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.21, sa.1, ss.52-56, 2011 (SCI-Expanded, Scopus, TRDizin)

130. The First Line Systemic Chemotherapy in Metastatic Gastric Carcinoma: A Comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) Versus Cisplatin and Fluorouracil (CF); Versus Epirubicin, Cisplatin and Fluorouracil (ECF) Regimens in Clinical Setting

KILIÇKAP S., YALÇIN Ş., ATEŞ Ö., Tekuzman G.

HEPATO-GASTROENTEROLOGY , cilt.58, sa.105, ss.208-212, 2011 (SCI-Expanded, Scopus)

131. Socio-demographic parameters in screening for breast cancer: Lessons from a population-based women's Health Project held in a province in Turkey

HAYRAN K. M., Abali H., KILIÇKAP S., MENTEŞ T., Aksoy H., Kemik A., et al.

JOURNAL OF BUON , cilt.15, sa.4, ss.726-731, 2010 (SCI-Expanded, Scopus)

132. The Effect on Prognosis of Postoperative CA 19-9 Level in Patients With Pancreatic Cancer

KILIÇKAP S., ARSLAN Ç.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.33, sa.3, ss.320, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

133. Fitting the Pieces of the POEMS Syndrome Jigsaw Puzzle-Guillain-Barre Syndrome in a Patient with Refractory Ascites: Case Report

Shorbagi A., ÖNAL İ. K., Onal E. D., KILIÇKAP S., BARIŞTA İ., Kansu T., et al.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI , cilt.30, sa.1, ss.352-355, 2010 (SCI-Expanded, Scopus)

134. A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection

KILIÇKAP S., Kars A., HAMALOĞLU E., ŞİMŞEK H.

MEDICAL ONCOLOGY , cilt.26, sa.4, ss.501-505, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

135. Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients

KILIÇKAP S., ARSLAN Ç.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION , cilt.301, sa.14, ss.1435, 2009 (SCI-Expanded, Scopus)

136. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma

KILIÇKAP S., Yavuz B., AKSOY S., Sahiner L., DİNÇER M., HARPUTLUOĞLU H., et al.

MEDICAL ONCOLOGY , cilt.25, sa.4, ss.437-442, 2008 (SCI-Expanded, Scopus)

137. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors

AKSOY S., KILIÇKAP S., Hayran M., HARPUTLUOĞLU H., KOCA E., Dede D. S., et al.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY , cilt.30, sa.3, ss.214-219, 2008 (SCI-Expanded, Scopus)

138. A case report: zoledronic acid-induced anterior uveitis

KILIÇKAP S., Ozdamar Y., ALTUNDAĞ M. K., DİZDAR Ö.

MEDICAL ONCOLOGY , cilt.25, sa.2, ss.238-240, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

139. Characteristics of breast cancer patients with central nervous system metastases: A single-center experience

Harputluoglu H., DİZDAR Ö., AKSOY S., KILIÇKAP S., Dede D. S., Ozisik Y., et al.

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION , cilt.100, sa.5, ss.521-526, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

140. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C

DİZDAR Ö., Tapan U., AKSOY S., Harputluoglu H., KILIÇKAP S., BARIŞTA İ.

EUROPEAN JOURNAL OF HAEMATOLOGY , cilt.80, sa.5, ss.381-385, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

141. Erectile dysfunction in successfully treated lymphoma patients

AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., et al.

SUPPORTIVE CARE IN CANCER , cilt.16, sa.3, ss.291-297, 2008 (SCI-Expanded, Scopus)

142. A decision-analytic model for early stage breast cancer: Lumpectomy vs mastectomy

Alogan G. B., Elele T., Hayran M., ERMAN M., KILIÇKAP S.

NEOPLASMA , cilt.55, sa.3, ss.222-228, 2008 (SCI-Expanded, Scopus)

143. The sign of Leser-Trelat

Kilickap S., Yalcin B.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.356, sa.21, ss.2184, 2007 (SCI-Expanded, Scopus)

144. Early and late arrhythmogenic effects of doxorubicin

Kilickap S., Barista I., Akgul E., Aytemir K., Aksoy S., Tekuzman G.

SOUTHERN MEDICAL JOURNAL , cilt.100, sa.3, ss.262-265, 2007 (SCI-Expanded, Scopus)

145. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient

Yilmaz R., Akoglu H., Yirkpantur A., Kilickap S., Arici M., Altun B., et al.

RENAL FAILURE , cilt.29, sa.1, ss.103-105, 2007 (SCI-Expanded, Scopus)

146. Rituximab-related viral infections in lymphoma patients

Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., et al.

LEUKEMIA & LYMPHOMA , cilt.48, sa.7, ss.1307-1312, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

147. Extensive exfoliative dermatitis induced by chlorambucil

Kilickap S., Kurt M., Aksoy S., Erman M., Turker A.

AMERICAN JOURNAL OF HEMATOLOGY , cilt.81, sa.11, ss.891-892, 2006 (SCI-Expanded, Scopus)

148. Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement

Kilickap S., Aksoy S., Dincer M., Saglam E. A., Yalcin S.

SOUTHERN MEDICAL JOURNAL , cilt.99, sa.10, ss.1137-1139, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

149. Gefitinib efficacy in relapsed small-cell lung cancer

DİNÇER M., Aksoy S., Kilickap S., Altundag K.

LUNG CANCER , cilt.53, sa.2, ss.255, 2006 (SCI-Expanded, Scopus)

150. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

Aksoy S., Abali H., Kilickap S., Erman M., Kars A.

CLINICAL AND LABORATORY HAEMATOLOGY , cilt.28, sa.3, ss.211-214, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

151. Nasopharynx carcinoma complicated with pneumocephalus

Dizdar O., Kilickap S., Aksoy S., Cizginer S., Erman M.

JOURNAL OF NEURO-ONCOLOGY , cilt.77, sa.1, ss.107-108, 2006 (SCI-Expanded, Scopus)

152. Lithium-associated hypothyroidism and thyroid papillary carcinoma: A case report

Aksoy S., Kilickap S., Erman M.

SOUTHERN MEDICAL JOURNAL , cilt.99, sa.3, ss.279-281, 2006 (SCI-Expanded, Scopus)

153. Metastatic granular cell tumor: A case report and review of the literature

Aksoy S., Abali H., Kilickap S., HARPUTLUOĞLU H., Erman M.

ACTA ONCOLOGICA , cilt.45, sa.1, ss.91-94, 2006 (SCI-Expanded, Scopus)

154. Nonconvulsive status epilepticus due to ifosfamide

Kilickap S., ÇAKAR M., Onal I., Tufan A., Akoglu H., Aksoy S., et al.

ANNALS OF PHARMACOTHERAPY , cilt.40, sa.2, ss.332-335, 2006 (SCI-Expanded, Scopus)

155. Acrocyanosis as a presenting symptom of Hodgkin lymphoma

Solak Y., Aksoy S., Kilickap S., Celik I.

AMERICAN JOURNAL OF HEMATOLOGY , cilt.81, sa.2, ss.151-152, 2006 (SCI-Expanded, Scopus)

156. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer

Aksoy S., Aksoy H., HARPUTLUOĞLU H., Kilickap S., Altundag K.

MEDICAL HYPOTHESES , cilt.67, sa.4, ss.744-746, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

157. Multivariate analysis of factors predictive of brain metastases in localised non-small call lung carcinoma

Kilickap S., Aksoy S., Erman M.

LUNG CANCER , cilt.49, sa.1, ss.129, 2005 (SCI-Expanded, Scopus)

158. Successful salvage therapy of resistant gestational trophoblastic disease with ifosfamide and paclitaxel

SHORBAGİ A., Aksoy S., Kilickap S., GÜLER N.

GYNECOLOGIC ONCOLOGY , cilt.97, sa.2, ss.722-723, 2005 (SCI-Expanded, Scopus)

159. Doxorubicin-induced second degree and complete atrioventricular block

Kilickap S., AKGUL E., Aksoy S., Aytemir K., Barista I.

EUROPACE , cilt.7, sa.3, ss.227-230, 2005 (SCI-Expanded, Scopus)

160. Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma

Aksoy S., Abali H., Kilickap S., GÜLER N.

JOURNAL OF NEURO-ONCOLOGY , cilt.71, sa.3, ss.333-334, 2005 (SCI-Expanded, Scopus)

161. Fludarabine phosphate may be useful in the treatment of graft-versus-host disease

Aksoy S., Abali H., Kilickap S., DİNÇER M., Erman M.

MEDICAL HYPOTHESES , cilt.64, sa.6, ss.1150-1152, 2005 (SCI-Expanded, Scopus)

162. CA 19-9 measurement as a screening: Higher cost, lower survival

Kilickap S., Abali H., Aksoy S., Celik I.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY , cilt.19, sa.12, ss.1428, 2004 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 55

1. Akciğer Kanserli Hastalarda Günlük Yaşam Aktiviteleri İle Ilişkili Parametrelerin Incelenmesi

ŞAHİN H., SAĞLAM M., VARDAR YAĞLI N., KILIÇ K., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al.

Türk Toraks Derneği 23.Yıllık Kongresi Bildiri Kitabı, Türkiye, 15 - 18 Ekim 2020, ss.147, (Özet Bildiri)

2. Multi-dimensional evaluation of daily living activities in lung cancer

ŞAHİN H., SAĞLAM M., VARDAR YAĞLI N., KILIÇ K., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al.

European Respiratory Society Virtual Congress, 7 - 09 Eylül 2020, cilt.56, ss.2931, (Özet Bildiri)

3. Evaluation of functional exercise capacity using two-field test in lung cancer patients

VARDAR YAĞLI N., KILIÇ K., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S.

European Respiratory Society Virtual Congress, 7 - 09 Eylül 2020, cilt.56, ss.278, (Özet Bildiri)

4. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

5. outcomes of patients with resected pancreatic ductal adenocarcinoma

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.

9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri)

6. Gemcitabine Based Trimodality Treatment in Patients WithMuscle Invasive Bladder Cancer: Hacettepe University Experience

Esen Ç. S. B., HÜRMÜZ P., KILIÇKAP S., ÖZYİĞİT G., AKYOL H. F.

6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 Kasım - 01 Aralık 2019, cilt.5, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

7. Determinants of Respiratory Muscle Strength in Lung Cancer

Kilic K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.

European-Respiratory-Society (ERS) International Congress, Madrid, İspanya, 28 Eylül - 02 Ekim 2019, cilt.54, (Özet Bildiri) Sürdürülebilir Kalkınma

8. Kolon kanseri tedavisi sonrası oksijen tüketimi, solunum kas kuvveti ve enduransı, fiziksel fonksiyon ve yorgunluğun incelenmesi: olgu sunumu

SANVER M. F., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S.

7. Ulusal Fizyoterapi ve Rehabilitasyon Kongresi, Türkiye, 18 - 20 Nisan 2019, cilt.30, ss.155, (Özet Bildiri)

9. Tip 2 diyabetli bireylerin fiziksel aktivite düzeyleri ve sağlıklı yaşam biçimi davranışlarının incelenmesi

SANVER M. F., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S.

7. Ulusal Fizyoterapi ve Rehabilitasyon Kongresi, Türkiye, 18 - 20 Nisan 2019, cilt.30, ss.154-155, (Özet Bildiri)

10. IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY)

Ramos-Casals M., Lambotte O., Kostine M., Calabrese L., Suarez-Almazor M., Bingham C., et al.

Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.607-608, (Özet Bildiri)

11. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

12. Akciğer kanserinde yürüme sırasındaki işin solunum kas kuvveti ile ilişkisi

VARDAR YAĞLI N., KILIÇ K., SAĞLAM M., İNAL İNCE D., ÇALIK KÜTÜKCÜ E., KILIÇKAP S.

Türk Toraks Derneği 22.Yıllık Kongresi, Türkiye, 10 - 14 Nisan 2019, ss.490, (Özet Bildiri)

13. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE

HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., et al.

ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

14. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER

HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., et al.

ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, cilt.1, ss.11, (Tam Metin Bildiri)

15. Metastatic Choroidal Melanoma: Single Center Experience

AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.

2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, ss.1-48, (Tam Metin Bildiri)

16. Do cancer treatments affect pain perception?

KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.

28th European Respiratory Society Annual Congress, 15 - 19 Eylül 2018, cilt.52, ss.2468, (Özet Bildiri) Sürdürülebilir Kalkınma

17. Respiratory muscle strength, respiratory muscle endurance, functional capacity and cognitive status in lung cancer patients

KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.

28th European Respiratory Society Annual Congress, 15 - 19 Eylül 2018, cilt.52, ss.2477, (Özet Bildiri) Sürdürülebilir Kalkınma

18. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”

GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al.

2018 ASCO, Chicago, Amerika Birleşik Devletleri, 1 - 05 Haziran 2018, (Özet Bildiri)

19. Yüksek Dereceli Rekürren Glial Tümör Tanılı Hastada Bevacizumabın Olası Bir Yan Etkisi Olarak Multipl Arteriovenöz Malformasyon

ELMALI DOĞAN A., MUT AŞKUN M., YÜCE SARI S., KILIÇKAP S., ZORLU A. F., YAZICI G.

13.ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Türkiye, 27 Nisan - 01 Mayıs 2018

20. Akciğer kanserli hastalarda kognitif durumun fonksiyonel kapasite ve fiziksel aktivite ile ilişkisi

KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., ARIKAN H., İNAL İNCE D., et al.

Türk Toraks Derneği 21.Yıllık Kongresi, Türkiye, 11 - 15 Nisan 2018, ss.326, (Özet Bildiri) Sürdürülebilir Kalkınma

21. Akciğer kanserli bireylerde solunum kas enduransının değerlendirilmesi

KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.

Türk Toraks Derneği 21.Yıllık Kongresi, Türkiye, 11 - 15 Nisan 2018, ss.324, (Özet Bildiri) Sürdürülebilir Kalkınma

22. Akciğer kanserli bireylerde ağrı durumunun değerlendirmesi

KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.

1. Kardiyopulmoner Rehabilitasyon Kongresi, Türkiye, 22 Mayıs - 25 Kasım 2017, cilt.29, (Özet Bildiri) Sürdürülebilir Kalkınma

23. Akciğer kanserinde kognitif durumun incelenmesi

KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al.

1. Kardiyopulmoner Rehabilitasyon Kongresi, Türkiye, 22 - 25 Kasım 2017, cilt.29, (Özet Bildiri) Sürdürülebilir Kalkınma

24. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi

GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

25. Brain Tissue Follow-up Using Dynamic Susceptibility Contrast-Enhanced and Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging on Lesions Categorized by Apparent Diffusion Coefficient Values in Glioblastoma

OMAY B., ARDALI S., MUT AŞKUN M., KILIÇKAP S., ERMAN M., KARLI OĞUZ H. K.

Radiology Society of North America, 26 Kasım - 01 Aralık 2017, (Özet Bildiri)

26. Erlotinib tedavisine direnç gösteren akciğer kanseri olgusu

BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., KÖKSAL D.

TÜSAD 2017, Türkiye, 14 - 17 Ekim 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

27. Opere evre 1A küçük hücreli dışı akciğer kanserli hastada erken nüks mü biyolojik yapıştırıcı reaksiyonu mu?

KÖKSAL D., BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., DOĞAN R.

TÜSAD 2017, Türkiye, 14 - 17 Ekim 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

28. Erlotinib tedavisine direnç gelişen akciğer adenokanseri olgusu

BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., KÖKSAL D.

TÜSAD 2017, Türkiye, 14 - 17 Ekim 2017, (Özet Bildiri)

29. Reinforcement of mental health in an interaction group of cancer patients

HAYRAN K. M., Kamışlı S., küçükçoban ş., ÇELİK İ., KILIÇKAP S., YÜCE D.

2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

30. Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinic

YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.

2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri)

31. Cancer patients and oncology nursing from the perspectives of oncology nurses in Turkey

Kamışlı S., YÜCE D., karakılıç B., KILIÇKAP S., HAYRAN K. M.

2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

32. Characteristics of Turkish colorectal cancer patients and bevacizumab preference.

Cicin I., Gumus M., Uncu D., Ozkan M., Kilickap S., Elkiran T. E., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) Sürdürülebilir Kalkınma

33. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program

AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.

7th ECTOH Conference on Tobacco or Health, Porto, Portekiz, 22 - 25 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

34. Tirozin Kinaz İnhibitörü Kaynaklı Tiroid Fonksiyon Bozukluğu

TECEN K., ÖZDEMİR N., KARA E., EKİNCİOĞLU A., DEMİRKAN S. K., ERMAN M., et al.

18. ULUSAL İÇ HASTALIKLARI KONGRESİ, Türkiye, 12 - 16 Ekim 2016, (Özet Bildiri)

35. Using geographical information systems to describe quality of life as a function of distance in cancer patients

HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., et al.

ISPOR Asia Pacific Meeting 2016, 3 - 06 Eylül 2016, cilt.19, ss.892, (Özet Bildiri)

36. Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.

Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Yilmaz F. M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

37. The clinical role of Ga-68 DOTATE PET-CT in patients with neuroendocrine tumors

TUNCEL M., KILIÇKAP S., Akdemir E.

28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri)

38. Adaptation of an ensemble of complementary neural networks with adjusted average error to other prediction models

YILMAZ IŞIKHAN S., KARABULUT E., KILIÇKAP S.

International Society for Clinical Biostatistics 36th Annual Conference, Utrecht, Hollanda, 23 - 27 Ağustos 2015, (Özet Bildiri)

39. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.

ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

40. Turkish National Colon Cancer Registry.

Benekli M., Dumanli E., Kilickap S., Uncu D., Aliustaoglu M., Cicin I., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

41. Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.

Benekli M., Altundag K., Dumanli E., Isikdogan A., Karaoglu A., Tekin S. B., et al.

42. Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.

Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., et al.

43. Turkish National Gastric Cancer Registry.

Buyukberber S., Dumanli E., Uncu D., Ozkan M., Uslu R., Dogu G. G., et al.

44. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.

Coskun U., Altundag K., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al.

45. Turkish National Breast Cancer Registry.

Altundag K., Dumanli E., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al.

46. Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.

Kilickap S., Altundag K., Dumanli E., Gumus M., Uslu R., Ozyilkan O., et al.

47. Clinical impact of Ga-68-DOTATATE in patients with neuroendrocrine tumors

TUNCEL M., KILIÇKAP S., Akdemir E.

3rd Theranostics World Congress on Gallium-68 and PRRT, Maryland, Amerika Birleşik Devletleri, 12 - 14 Mart 2015, cilt.56, (Özet Bildiri)

48. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML

AKSU S., AKTİMUR S., ARİCA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., et al.

20th Congress of the European Hematology Association Vienna, Austria June 11-14,2015, 11 - 14 Haziran 2014, (Tam Metin Bildiri)

49. The diagnostic and prognostic value of UHRF-1 and p53 in gastric cancer.

Babacan N. A., Egilmez R., Yucel B., Seker M. M., Parlak I., Kacan T., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

50. Could the neutrophil to lymphocyte ratio be a poor prognostic factor for lung cancers?

Kacan T., Babacan N., Seker M. M., Yucel B., Behceci A., Gedikil M. A., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

51. İYİ DİFERANSİYE TİROİT KANSERLERİNDE TSH R METİLASYONUNUN ÖNEMİ

KARTAL K., KÖSEMEHMETOĞLU K., ÖNDER S. Ç., KILIÇKAP S., GÜLER TEZEL Y. G., KAYNAROĞLU Z. V.

19. Ulusal Cerrahi Kongresi, Türkiye, 16 - 20 Nisan 2014, (Özet Bildiri) Sürdürülebilir Kalkınma

52. İyi Diferansiye Tiroit Kanserlerinde Tsh R Metilasyonunun Önemi

KARTAL K., KÖSEMEHMETOĞLU K., ÖNDER S. Ç., KILIÇKAP S., GÜLER TEZEL Y. G., KAYNAROĞLU Z. V.

19. Ulusal Cerrahi Kongresi, Türkiye, 16 - 20 Nisan 2014, (Özet Bildiri) Sürdürülebilir Kalkınma

53. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience

Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al.

Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

54. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study

Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma